Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 79Triple Negative Breast Neoplasms 9Stomach Neoplasms 8Inflammatory Breast Neoplasms 6Carcinoma, Hepatocellular 6Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Sarcoma 2Primary Breast Cancer 2Pathologic Complete Response 2Lung Neoplasms 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Nasopharyngeal Carcinoma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Letrozole 5Paclitaxel 4atamestane 3Toremifene 3Tamoxifen 3Cyclophosphamide 3Estrogen Receptor Modulators 2Epirubicin 2Doxorubicin 2Docetaxel 2Carboplatin 2Capecitabine 2Aromatase Inhibitors 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2pertuzumab 1ferric carboxymaltose 1atezolizumab 1Vinorelbine 1Trastuzumab 1TP protocol 1Surgical Procedures, Operative 1Radiotherapy 1Medroxyprogesterone 1Fulvestrant 1Fluorouracil 1Estrogens, Conjugated (USP) 1Cisplatin 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Ductal, Breast × Epirubicin × Clear all
NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

RenJi Hospital

Phase 3 Unknown
290 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡